CYCN
Price:
$2.93
Market Cap:
$7.94M
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic neph...[Read more]
Industry
Biotechnology
IPO Date
2019-03-18
Stock Exchange
NASDAQ
Ticker
CYCN
According to Cyclerion Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.68. This represents a change of -17.10% compared to the average of -0.82 of the last 4 quarters.
The mean historical PE Ratio of Cyclerion Therapeutics, Inc. over the last ten years is -2.03. The current -0.68 PE Ratio has changed 3.26% with respect to the historical average. Over the past ten years (40 quarters), CYCN's PE Ratio was at its highest in in the September 2023 quarter at 0.28. The PE Ratio was at its lowest in in the December 2018 quarter at -55.22.
Average
-2.03
Median
-1.29
Minimum
-5.39
Maximum
-0.37
Discovering the peaks and valleys of Cyclerion Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 107.97%
Maximum Annual PE Ratio = -0.37
Minimum Annual Increase = -79.21%
Minimum Annual PE Ratio = -5.39
Year | PE Ratio | Change |
---|---|---|
2023 | -0.37 | -42.76% |
2022 | -0.65 | -50.04% |
2021 | -1.30 | 1.80% |
2020 | -1.28 | 107.97% |
2019 | -0.62 | -79.21% |
2018 | -2.96 | -18.51% |
2017 | -3.63 | -32.57% |
The current PE Ratio of Cyclerion Therapeutics, Inc. (CYCN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.78
5-year avg
-0.84
10-year avg
-2.03
Cyclerion Therapeutics, Inc.’s PE Ratio is less than Kronos Bio, Inc. (-0.58), greater than Larimar Therapeutics, Inc. (-8.80), greater than Addex Therapeutics Ltd (-81.79), less than Achilles Therapeutics plc (-0.45), less than Lipella Pharmaceuticals Inc. (-0.00), less than Senti Biosciences, Inc. (-0.23), less than Fennec Pharmaceuticals Inc. (54.24), greater than Monopar Therapeutics Inc. (-1.18), less than Applied Molecular Transport Inc. (-0.14), greater than Cardio Diagnostics Holdings, Inc. (-0.75), greater than Sigilon Therapeutics, Inc. (-1.90), less than Sonnet BioTherapeutics Holdings, Inc. (-0.55), less than ZyVersa Therapeutics, Inc. (-0.10), less than X4 Pharmaceuticals, Inc. (7.41), greater than Axcella Health Inc. (-10.73), less than Magenta Therapeutics, Inc. (-0.04), less than Kezar Life Sciences, Inc. (-0.41), less than ContraFect Corporation (-0.11), greater than ZIVO Bioscience, Inc. (-2.46), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Erasca, Inc. (-3.94), less than Forte Biosciences, Inc. (-0.39),
Company | PE Ratio | Market cap |
---|---|---|
-0.58 | $59.36M | |
-8.80 | $513.64M | |
-81.79 | $17.80M | |
-0.45 | $29.58M | |
-0.00 | $4.10M | |
-0.23 | $13.14M | |
54.24 | $144.76M | |
-1.18 | $8.41M | |
-0.14 | $11.01M | |
-0.75 | $6.94M | |
-1.90 | $56.22M | |
-0.55 | $4.53M | |
-0.10 | $2.70M | |
7.41 | $109.78M | |
-10.73 | $0 | |
-0.04 | $42.44M | |
-0.41 | $40.82M | |
-0.11 | $1.72M | |
-2.46 | $37.03M | |
-3.19 | $181.50M | |
-3.94 | $807.96M | |
-0.39 | $11.11M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyclerion Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cyclerion Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cyclerion Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Cyclerion Therapeutics, Inc. (CYCN)?
What is the highest PE Ratio for Cyclerion Therapeutics, Inc. (CYCN)?
What is the 3-year average PE Ratio for Cyclerion Therapeutics, Inc. (CYCN)?
What is the 5-year average PE Ratio for Cyclerion Therapeutics, Inc. (CYCN)?
How does the current PE Ratio for Cyclerion Therapeutics, Inc. (CYCN) compare to its historical average?